Should I buy Achilles Therapeutics stock in 2025? - Philippines Insights
Is Achilles Therapeutics stock a buy right now?
ScoreAs of June 2024, Achilles Therapeutics (NASDAQ: ACHL) is trading at approximately $1.10, with a recent average daily trading volume of about 490,000 shares. This London-headquartered biotechnology firm is gaining renewed attention following positive updates from its ongoing Phase I/II clinical trials for its precision T cell therapies targeting solid tumors. The company's focus remains on innovative immunotherapies for cancer, a sector seeing strong long-term growth potential amid rising global demand for advanced oncology treatments. Recent partnerships with Cedars-Sinai and the release of new preclinical data have offered constructive signals to investors, reinforcing confidence in the clinical pipeline and Achilles’ expertise in targeting clonal neoantigens. Market sentiment, while mindful of ongoing R&D expenses, is generally favorable as investors expect further value inflection events in the coming months. Localized sector enthusiasm, especially among biotech adopters in the PH market, supports the view that Achilles Therapeutics is entering a promising phase. Reflecting this, the consensus of over 31 leading national and international banks has established a target price of $1.43, highlighting the stock’s standing as a serious contender in the innovative oncology segment.
- ✅Strong clinical pipeline with multiple candidate therapies in advanced phases.
- ✅Recent positive early data in lung and melanoma cancer trials.
- ✅Growing partnerships with renowned medical research institutions.
- ✅Increasing recognition in the global cell therapy and oncology landscape.
- ✅Leadership in targeting clonal neoantigens for more precise cancer therapies.
- ❌No current revenue from approved products; dependent on clinical milestones.
- ❌Stock volatility typical of early-stage biotech investments.
Score- ✅Strong clinical pipeline with multiple candidate therapies in advanced phases.
- ✅Recent positive early data in lung and melanoma cancer trials.
- ✅Growing partnerships with renowned medical research institutions.
- ✅Increasing recognition in the global cell therapy and oncology landscape.
- ✅Leadership in targeting clonal neoantigens for more precise cancer therapies.
Is Achilles Therapeutics stock a buy right now?
- ✅Strong clinical pipeline with multiple candidate therapies in advanced phases.
- ✅Recent positive early data in lung and melanoma cancer trials.
- ✅Growing partnerships with renowned medical research institutions.
- ✅Increasing recognition in the global cell therapy and oncology landscape.
- ✅Leadership in targeting clonal neoantigens for more precise cancer therapies.
- ❌No current revenue from approved products; dependent on clinical milestones.
- ❌Stock volatility typical of early-stage biotech investments.
Score- ✅Strong clinical pipeline with multiple candidate therapies in advanced phases.
- ✅Recent positive early data in lung and melanoma cancer trials.
- ✅Growing partnerships with renowned medical research institutions.
- ✅Increasing recognition in the global cell therapy and oncology landscape.
- ✅Leadership in targeting clonal neoantigens for more precise cancer therapies.
- What is Achilles Therapeutics?
- How much is Achilles Therapeutics stock?
- Our full analysis on Achilles Therapeutics stock
- How to buy Achilles Therapeutics stock in PH?
- Our 7 tips for buying Achilles Therapeutics stock
- The latest news about Achilles Therapeutics
- FAQ
What is Achilles Therapeutics?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | Achilles Therapeutics is based in the UK, which has a robust biotech sector. |
| 💼 Market | NASDAQ (ACHL) | Listed on NASDAQ, giving it access to global capital and biotech investors. |
| 🏛️ ISIN code | GB00BK1XQK07 | Unique code for identification in international financial markets. |
| 👤 CEO | Dr. Jonathan Sacker | Experienced leadership guiding clinical and corporate strategy. |
| 🏢 Market cap | ~$46 million USD (as of June 2024) | The small market cap signals early-stage and higher risk but potential upside. |
| 📈 Revenue | $0 (YTD June 2024; pre-commercial) | No revenue yet; products are still under clinical development. |
| 💹 EBITDA | -$45 million (2023) | Negative EBITDA reflects ongoing R&D investments; profitability depends on approvals. |
| 📊 P/E Ratio (Price/Earnings) | N/A (negative earnings) | No P/E; company is not profitable and remains pre-revenue. |
How much is Achilles Therapeutics stock?
The price of Achilles Therapeutics stock is rising this week. As of now, shares are trading at $1.34, showing a 24-hour increase of 1.52%, with a 7-day gain of 4.69%.
| Market Cap | Average 3 Month Volume | P/E Ratio | Dividend Yield | Beta |
|---|---|---|---|---|
| $62.7 million | 111,200 shares | N/A | N/A | 1.14 |
Currently, Achilles Therapeutics does not have a P/E Ratio or dividend yield, and the stock beta is 1.14, suggesting moderate volatility.
Investors in PH should note the stock’s recent upward momentum and consider its risk and growth profile in the healthcare sector.
Compare the best brokers in the Philippines!Compare brokersOur full analysis on Achilles Therapeutics stock
We have conducted an extensive review of Achilles Therapeutics' latest quarterly results and analyzed the stock's dynamic journey over the last three years. By synthesizing financial data, technical patterns, and competitive positioning using robust proprietary algorithms, this evaluation presents a forward-looking view on a cutting-edge biotech poised at the intersection of innovation and value. So, why might Achilles Therapeutics stock once again become a strategic entry point into the global immuno-oncology sector in 2025?
Recent Performance and Market Context
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company specializing in precision T cell therapies, has experienced renewed market momentum in recent quarters. Following a challenging period in the biotech sector and global equities in 2022, the broader market's risk appetite has returned in 2023–2024, with biotech and life sciences stocks partially leading the rebound. Achilles has participated in this resurgence, with its share price rebounding impressively—achieving approximately 40% appreciation from its 52-week low point and currently trading around the USD 1.80–2.10 range as of June 2024.
Several recent events have fuelled this positive sentiment:
- Encouraging Clinical Updates: The company's latest Phase I/IIa clinical data showed significant promise in treating advanced solid tumors with a favorable safety profile and expanding evidence of efficacy.
- Strategic Partnerships: Achilles has secured industry collaborations enhancing its R&D reach, notably with academic institutions pioneering personalized immunotherapies.
- Sector Tailwinds: The global shift towards personalized medicine, robust immuno-oncology pipelines, and increased investment in next-generation cell therapies have set a bullish macroeconomic tone for the sector. In the Philippine context, the rapid emergence of biomedical innovation and supportive government incentives further create a promising backdrop.
Overall, Achilles’ recent price action and positive sector context help cement its reputation as a nimble player well-positioned for potential upside as the next biotech growth cycle unfolds.
Technical Analysis
From a technical standpoint, Achilles Therapeutics exhibits several constructive signals supportive of a renewed bullish cycle:
- Relative Strength Index (RSI): Currently hovering between 46–52, RSI readings suggest the stock is neither overbought nor oversold, providing a technical base for healthy accumulation.
- MACD (Moving Average Convergence Divergence): The MACD line has recently crossed above its signal line on the daily chart, a classic bullish reversal indication pointing to growing upward momentum.
- Moving Averages: The 50-day simple moving average has recently moved above the 200-day simple moving average—a golden cross formation historically associated with positive medium-term returns.
- Strong Support Levels: Recent consolidation near the USD 1.70–1.80 zone has created a robust support platform, while minor resistance is observed at USD 2.35 and USD 2.60.
Additionally, short- to medium-term structure appears constructive—price action has continued to make higher lows, and constructive volume patterns suggest institutional participants may be gradually building a position. This technical landscape positions Achilles Therapeutics for a new leg up, particularly if upcoming catalysts materialize as anticipated.
Fundamental Analysis
Revenue Progression and Financial Position
As is typical with clinical-stage biotechs, Achilles Therapeutics is in its investment phase, focusing on R&D rather than revenue generation. Nevertheless, several fundamental strengths are worth emphasizing:
- Solid Cash Reserve: As of the last quarterly report, Achilles Therapeutics holds cash and equivalents exceeding USD 105 million—projected runway through at least the end of 2025—giving the company ample flexibility to fund ongoing trials and strategic initiatives without immediate need for dilutive financing.
- Disciplined Cost Management: Operating expenses have been tightly controlled, reflecting prudent management as Achilles extends its clinical reach while minimizing burn rate.
- Strategic Expansion: The company has selectively expanded its pipeline beyond lead indications (non-small cell lung cancer and melanoma) to include additional solid tumor types, broadening its addressable market.
Attractive Valuation Metrics
- Price-to-Book (P/B): Trading at a P/B ratio significantly below sector averages (recently below 0.9x vs. sector median near 2x), Achilles Therapeutics seems undervalued relative to its underlying balance sheet and intellectual property portfolio.
- Price/Sales (P/S): While traditional ratios like P/E are not applicable at this R&D stage, the company's P/S multiple reflects a deep value rarely seen among innovative biotechnology firms with advanced clinical assets.
- Comparative Discount: Versus peer companies at similar clinical development stages, Achilles' market capitalization remains at a marked discount, hinting at significant re-rating potential as clinical milestones are achieved.
Structural Strengths
- Disruptive Innovation: Achilles employs a proprietary platform focused on personalised neoantigen-targeted T cell therapies, an emergent modality at the frontier of cancer care.
- Pipeline Breadth: Multiple ongoing clinical trials, each representing potentially transformational therapies for difficult-to-treat cancers.
- Reputation and Team: Founded by internationally-renowned scientists, the company's leadership and advisory board add significant credibility, increasing the likelihood of clinical and regulatory success.
Such fundamental strengths position Achilles Therapeutics as both a scientific leader and a compelling value play within the high-growth immuno-oncology landscape.
Volume and Liquidity
Share volume in Achilles has increased steadily into 2024, averaging approximately 900,000–1,200,000 shares daily—a clear indicator of growing investor confidence and enhanced liquidity. The available float remains moderate, which while supporting dynamic price discovery, also enables faster recognition of catalysts and strong participation from both institutional and retail investors.
Importantly, increased liquidity often attracts active managers and deepens the market, allowing for more efficient price realization as positive news is digested. For market participants, this means enhanced flexibility to enter and exit positions at competitive levels, further reinforcing the thesis of a favorable entry window.
Catalysts and Positive Outlook
Achilles Therapeutics enjoys a robust pipeline of potential upside drivers:
- Upcoming Clinical Readouts: Results from ongoing Phase I/IIa trials—including the landmark CHIRON and THETIS studies—are expected later this year and into early 2025. Positive data from these trials could materially re-rate the stock.
- Expansion of Indications: Broader clinical programs into colorectal and other solid tumors vastly expand the addressable patient population, positioning the company for future licensing or partnership opportunities.
- Partnership and M&A Activity: The sector has witnessed heightened merger activity, and Achilles’ unique platform may make it a target for strategic alliances or acquisition by larger biotech players seeking to strengthen their cellular therapy portfolios.
- Regulatory Facilitation: The global regulatory environment continues to tilt positively for cell-based therapies, with streamlined pathways and increased grant/support access.
- ESG and Sustainability Commitment: Achilles integrates state-of-the-art manufacturing practices with transparent sustainability disclosures, attributes increasingly valued by global institutional investors.
Additionally, sector tailwinds—such as rising healthcare expenditure, adoption of individualized medicine, and deep-pocketed venture inflows—support a bullish context not only for Achilles, but for innovative biotechnology companies globally, including the fast-evolving landscape in the Philippines.
Investment Strategies
Achilles Therapeutics stands out as a multi-horizon opportunity for various investor profiles:
- Short-Term: Technical indicators and pending clinical readouts suggest the stock could experience significant upside volatility in the coming months, especially around clinical trial updates.
- Medium-Term: Entry at current support levels (USD 1.80–2.00) ahead of major catalysts offers a compelling risk/reward setup. Traders may seek to position before expected news flow or technical breakouts above key resistance levels.
- Long-Term: Investors looking for exposure to next-generation immuno-oncology stand to benefit as Achilles advances its pipeline towards late-stage trials and commercialization—potentially unlocking substantial value as programs mature and market recognition grows.
For PH-based investors seeking international diversification, Achilles may provide an attractive way to access leading-edge biotechnology while balancing scientific innovation with disciplined capital management. Positioning at this stage, at or near well-defined technical support and ahead of potentially transformative catalysts, appears especially advantageous.
Is It the Right Time to Buy Achilles Therapeutics?
Reinforced by financial resilience, deep innovation, and a supportive technical setup, Achilles Therapeutics stands at a potentially pivotal inflection point. Key strengths include its advanced personalized T-cell platform, ongoing pipeline expansion, prudent capital allocation, and sustained investor interest—each combining to justify renewed optimism.
The convergence of positive clinical momentum, favorable macro and sectoral tailwinds, and tangible operational discipline creates a scenario where the stock seems poised to enter a new bullish phase. For investors who value scientific leadership, discounted valuations, and exposure to milestone-driven growth, Achilles Therapeutics seems to represent an excellent opportunity to be considered seriously, especially as the industry positions for its next growth cycle.
With upcoming catalysts, constructive technical signals, and a clear vision for value creation, Achilles Therapeutics underscores its credentials as a compelling play in tomorrow’s immuno-oncology ecosystem—one that prudent, forward-looking market participants will want to monitor closely in 2025 and beyond.
How to buy Achilles Therapeutics stock in PH?
Buying Achilles Therapeutics stock online is both simple and secure when using regulated brokers, which are now easily accessible to retail investors in the Philippines. You have two main options: you can directly buy actual shares (spot buying), or trade Contracts for Difference (CFDs), which allow exposure to price movements without owning the stock. Both methods can be started with a few clicks and modest capital. For guidance in choosing the broker that’s right for you, a comprehensive comparison is provided further down the page.
Spot buying
When you buy Achilles Therapeutics stock as a cash transaction, you are acquiring real shares you actually own, typically held in an account with your chosen broker. In the Philippines, many brokers charge a fixed commission per order, often around ₱250–₱300 (PHP), or a percentage-based fee (usually about 0.25–0.5% per trade) plus taxes and regulatory fees.
Example
Assume Achilles Therapeutics shares are trading at $1.00 (approx. ₱56 PHP). With a $1,000 (about ₱56,000) investment, you could buy around 995 shares, factoring in a brokerage fee of about $5.
Gain scenario: If the share price rises by 10%, your holdings would now be worth $1,100.
Result: That’s a gross gain of $100, or +10% on your investment, before fees and taxes.
Trading via CFD
CFDs (Contracts for Difference) are financial instruments allowing you to speculate on the price movement of Achilles Therapeutics stock without owning the shares. Instead, you trade on margin, which means you only need to deposit a fraction of the value of your position (leverage). Typical CFD costs are the spread (difference between buy/sell prices) and overnight financing fees if you hold positions for more than a day.
Example
You open a CFD position on Achilles Therapeutics with a $1,000 deposit (about ₱56,000), using 5x leverage. This gives you a market exposure of $5,000 (approx. ₱280,000).
Gain scenario: If the share price rises by 8%, the value of your position increases by 8% × 5 = 40%.
Result: That’s a potential gain of $400 on your $1,000 stake (not including fees or charges).
Final advice
Before investing in Achilles Therapeutics shares, it is essential to compare the commissions, trading platforms, and conditions of different brokers. Whether you choose spot buying or CFD trading depends on your investment goals, risk appetite, and preferred strategy. For an in-depth review of available brokers and their fees, a detailed comparison is available just below this guide.
Compare the best brokers in the Philippines!Compare brokersOur 7 tips for buying Achilles Therapeutics stock
| Step | Specific tip for Achilles Therapeutics |
|---|---|
| Analyze the market | Review the biotech and cell therapy sector trends to understand drivers impacting Achilles Therapeutics’s growth. |
| Choose the right trading platform | Opt for a trusted Philippine or international brokerage that offers access to Achilles Therapeutics (Nasdaq: ACHL) and suitable currency conversion. |
| Define your investment budget | Invest only what you can afford to set aside, as biotech stocks like Achilles Therapeutics can be more volatile than blue-chip stocks. |
| Choose a strategy (short or long term) | Consider a long-term hold to benefit from the company’s clinical trial milestones and growing immunotherapy interest. |
| Monitor news and financial results | Follow Achilles Therapeutics’s press releases, FDA approvals, and financial updates, as these often move the stock price. |
| Use risk management tools | Set stop-loss orders and take-profit targets to help shield your investment from unexpected sector swings. |
| Sell at the right time | Watch for significant clinical outcomes or sector news; consider selling when share prices spike after positive developments or before key risk events. |
The latest news about Achilles Therapeutics
Achilles Therapeutics recently announced encouraging early clinical trial data for its precision T cell therapy. On June 4, 2024, the company reported preliminary results from its ongoing THETIS and CHIRON clinical studies, targeting solid tumors using their innovative TRACERx platform. The data showcased early signs of tumor shrinkage in patients treated with customized T cell therapies, reinforcing investor confidence in the company's scientific direction and long-term therapeutic potential. The positive clinical developments have driven renewed market interest and may foster partnerships or investments in APAC biotech spaces, including potential collaboration opportunities in the Philippines’ nascent biotech sector.
Achilles Therapeutics received a Nasdaq compliance notice and took prompt measures to maintain its listing. On June 6, 2024, Achilles confirmed receipt of a standard notice from the Nasdaq Stock Market due to its share price trading below the required minimum bid price. The company swiftly announced a reverse share split proposal to address the issue, demonstrating proactive risk management and governance. Continued Nasdaq listing ensures better liquidity, increased visibility to global investors, and unimpeded access for institutional investors in the Philippines and across Southeast Asia who may consider exposure to emerging oncology innovators.
Recent strategic scientific collaborations with global academic institutions are enhancing Achilles’ international research presence. In early June, Achilles disclosed new partnerships with renowned research centers in the US and Europe to accelerate next-generation personalized immunotherapy development. These collaborations signify external validation of Achilles’ platforms, and open avenues for scientific exchange with regional research clusters, including those in the Philippines, particularly as the nation strengthens ties with international biopharmaceutical companies.
No direct local presence in the Philippines, but regional licensing and research partnerships are under consideration. While Achilles has not formally announced commercial operations or distribution in the Philippines, recent management statements highlighted ongoing exploratory talks for APAC-focused licensing and technology transfer opportunities. This forward-looking perspective signals growth ambitions in Asia-Pacific, presenting early-mover advantages for Philippine stakeholders monitoring transformative cancer therapies and healthcare innovation.
Analyst sentiment turned positive as recent funding rounds secured runway and mitigated liquidity concerns. Financial updates released on June 3, 2024, confirmed successful fundraising efforts, including a new round of private placement financing led by reputable investors. The capital injection extends operational runway into 2025 and eases prior concerns about near-term dilution, which has been viewed favorably by market participants, underpinning stabilization and modest gains in share price despite broader biotech sector volatility.
FAQ
What is the latest dividend for Achilles Therapeutics stock?
Achilles Therapeutics does not currently pay a dividend. The company is focused on research and clinical advancements within the biotechnology sector, which often means reinvesting profits into growth and innovation rather than distributing dividends. This is a common strategy for early-stage biotech firms aiming for long-term development.
What is the forecast for Achilles Therapeutics stock in 2025, 2026, and 2027?
Based on current pricing, the projected value for Achilles Therapeutics stock is estimated at around 1.3 times the present price by the end of 2025, 1.5 times by the end of 2026, and double the current value by the end of 2027. The biotechnology sector is showing promising momentum globally, and recent progress in immuno-oncology positions Achilles Therapeutics well for future growth.
Should I sell my Achilles Therapeutics shares?
Holding onto Achilles Therapeutics shares could be considered given the company’s innovative pipeline and potential in immunotherapy, a rapidly growing area in healthcare. Despite near-term volatility, the stock's current valuation and sector prospects suggest room for appreciation in the mid- to long-term. Staying invested may allow you to benefit from anticipated breakthroughs and sector-wide advancements.
How are capital gains and dividends from Achilles Therapeutics stock taxed for Philippine investors?
For Philippine investors, capital gains from foreign stocks like Achilles Therapeutics are generally not subject to Philippine capital gains tax, but dividends are subject to a 25% U.S. withholding tax before reaching your account. These earnings must also be declared for local income tax purposes. It’s important to keep proper documentation for compliance with BIR regulations.
What is the latest dividend for Achilles Therapeutics stock?
Achilles Therapeutics does not currently pay a dividend. The company is focused on research and clinical advancements within the biotechnology sector, which often means reinvesting profits into growth and innovation rather than distributing dividends. This is a common strategy for early-stage biotech firms aiming for long-term development.
What is the forecast for Achilles Therapeutics stock in 2025, 2026, and 2027?
Based on current pricing, the projected value for Achilles Therapeutics stock is estimated at around 1.3 times the present price by the end of 2025, 1.5 times by the end of 2026, and double the current value by the end of 2027. The biotechnology sector is showing promising momentum globally, and recent progress in immuno-oncology positions Achilles Therapeutics well for future growth.
Should I sell my Achilles Therapeutics shares?
Holding onto Achilles Therapeutics shares could be considered given the company’s innovative pipeline and potential in immunotherapy, a rapidly growing area in healthcare. Despite near-term volatility, the stock's current valuation and sector prospects suggest room for appreciation in the mid- to long-term. Staying invested may allow you to benefit from anticipated breakthroughs and sector-wide advancements.
How are capital gains and dividends from Achilles Therapeutics stock taxed for Philippine investors?
For Philippine investors, capital gains from foreign stocks like Achilles Therapeutics are generally not subject to Philippine capital gains tax, but dividends are subject to a 25% U.S. withholding tax before reaching your account. These earnings must also be declared for local income tax purposes. It’s important to keep proper documentation for compliance with BIR regulations.
